Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Trial Profile

Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radium 223 chloride (Primary) ; Abiraterone; Cabazitaxel; Docetaxel; Enzalutamide; Lutetium-177 PSMA therapy; Sipuleucel-T
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REASSURE
  • Sponsors Bayer
  • Most Recent Events

    • 19 Feb 2024 Planned primary completion date changed from 23 Nov 2024 to 2 Aug 2024.
    • 27 Jan 2024 Results of safety outcomes in patients with mCRPC treated with Ra-223 following external beam radiation therapy (EBRT) in the US,presented at the 2024 Genitourinary Cancers Symposium
    • 17 Jan 2024 According to a Bayer media release, company will also present new data from this REASSURE observational study evaluating the safety outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with XOFIGO (radium Ra 223 dichloride) following EBRT in the U.S. subset of patients enrolled at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top